• Skip to main content
  • Skip to primary sidebar
virology blog

virology blog

About viruses and viral disease

TWiV 902: Autoantibodies drive severe COVID-19

22 May 2022 Leave a Comment

TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19.

Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker

Click arrow to play
Download TWiV 902 (76 MB .mp3, 127 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

21 May 2022 Leave a Comment

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.

Click arrow to play
Download TWiV 901 (36 MB .mp3, 60 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

TWiV 900: Burning down the mouse

15 May 2022 Leave a Comment

TWiV celebrates 900 episodes, Vincent gives the Richard R. Ernst lecture, and we discuss why inflammasome activation in infected macrophages drives severe COVID-19.

Hosts: Vincent Racaniello, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker

Click arrow to play
Download TWiV 900 (65 MB .mp3, 108 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

Trial By Error: An Interview With Mt Sinai’s David Putrino About Long Covid, ME/CFS, and Related Issues

12 May 2022 12 Comments

By David Tuller, DrPH

David Putrino is a neuroscientist and physical therapist at Mt. Sinai Hospital in New York. He runs a research lab and a rehabilitation center that quickly became a magnet for patients grappling with what has come to be known as long Covid–what the US National Institutes of Health calls post-acute sequelae of SARS-CoV-2 (PASC). We spoke today about his background and how he began treating long Covid patients, the symptom of post-exertional malaise, the tendency to psychologize medical conditions like long Covid and ME/CFS, etc.

[Read more…] about Trial By Error: An Interview With Mt Sinai’s David Putrino About Long Covid, ME/CFS, and Related Issues

Fighting Viruses with Viruses

5 May 2022 2 Comments

by Gertrud U. Rey

Errors during viral replication can give rise to shortened and/or rearranged genomic sequences known as “defective viral genomes” (DVGs). Because DVGs often lack critical elements needed for replication and formation of new viral particles, virions containing DVGs can only complete a replication cycle if they co-infect a cell together with respective full-length (i.e., wild type) viruses. To replicate their genomes, DVGs often hijack missing proteins from the wild type viruses, a phenomenon that can result in suppression of wild type virus replication. There is increasing evidence to suggest that this suppression can be exploited for the development of antiviral agents.

Marco Vignuzzi at the Institut Pasteur has been exploring this idea by investigating the antiviral potential of DVGs produced during infection of cells with various viruses. In an effort to capture DVGs as they were formed in cell culture, Vignuzzi and colleagues infected mammalian and mosquito cells with Chikungunya virus, a mosquito-borne virus that causes symptoms similar to those caused by dengue virus. They then isolated newly emerging virions from the cells and used those particles to infect new cells – a cycle that was carried out 10 times in a technique known as serial passaging. Sequencing and quantification of viral genomes isolated from the last passage revealed that the number of DVGs increased by about 100,000 between the first and last passage. The most prevalent DVGs were sorted into four groups, with DVGs within each group having deletions of similar sizes and at similar genomic locations. Three of the groups included mostly DVGs derived from mammalian cells and the fourth group included mostly DVGs derived from mosquito cells.

To determine whether DVGs are also generated in an infected arthropod, the authors infected Aedes aegypti mosquitoes with Chikungunya virus by allowing them to feed on virus-infected blood. Ten days after infection, the mosquitoes were dissected, total RNA was isolated, and DVGs were identified by sequencing the RNA using DVG-specific primers. This analysis revealed that the DVGs produced in mosquitoes had similar deletion patterns and profiles as those produced in cell culture, suggesting that DVGs are generated both in cell culture and mosquitoes.

All subsequent studies were done using 20 mammalian- and mosquito-derived DVGs that occurred most frequently and persisted through all passages. To confirm that the DVGs were indeed defective and unable to replicate inside a cell in the absence of full-length virus, the authors introduced (i.e., “transfected”) RNA molecules encoding each DVG into mammalian cells and extracted total RNA from the cells at 8, 20, 28, and 44 hours post-transfection. DVG RNA was then quantified by PCR using primers specific for the respective DVGs. The authors observed that in contrast to wild type virus levels observed in control cells, which increased steadily over time, DVG levels decreased across all time points. This finding confirmed that in the absence of wild type virus DVG RNA was not replicated, but degraded over time.

To see whether the 20 DVGs actually interfered with replication of wild type virus, the authors transfected mammalian cells with a 1:1 ratio of an RNA encoding a DVG and an RNA encoding a full-length fluorescently-tagged wild type Chikungunya virus, so they could monitor the presence of the wild type virus by fluorescence microscopy at various timepoints. Wild type Chikungunya viruses transfected together with most DVG-encoding RNAs continued fluorescing strongly at 48 hours post-transfection, suggesting that most DVGs did not inhibit or reduce the replication of wild type virus when transfected at a 1:1 ratio. However, when the DVG/full-length virus ratio was increased to 10:1, fluorescence of full-length Chikungunya viruses decreased by 10 – 1,000-fold in the presence of almost all DVGs, suggesting that a higher ratio of most DVG RNAs increased the likelihood of these genomes to confiscate needed replication elements from wild type viruses and thus interfere with their reproduction. Interestingly, the smallest DVG with the biggest deletions did not seem to interfere with wild type virus replication, probably because this genome was missing too many elements and could not be adequately compensated by the presence of full-length virus. Overall, these results suggested that both mammalian- and mosquito cell-derived DVGs can interfere with wild type virus replication in mammalian cells. Remarkably, when this experiment was repeated in mosquito cells, most of the mosquito cell-derived DVGs that could inhibit wild type virus replication in mammalian cells were unable to do so in mosquito cells. Although the exact reason for this effect is unclear, it is possible that the prevalence of arthropod-borne viruses in mosquitoes has led these viruses to evolve some resistance to the effects of DVGs during viral replication in mosquitoes.

The authors also found that although most DVGs only inhibited Chikungunya virus strains that were closely related to the strain they were derived from, a small number of DVGs also inhibited more distantly related viruses like Sindbis virus, suggesting that DVGs may be capable of inhibiting a broad range of viruses.

In a final set of experiments aimed to evaluate the ability of the DVGs to prevent viral spread within mosquito hosts, the authors injected mosquitoes with DVG-encoding RNAs, and two days later they infected them with a fluorescently-tagged wild type Chikungunya virus. A control group of mosquitoes was only infected with Chikungunya virus but did not receive any DVGs. Five days after infection, the mosquitoes were killed and analyzed for infection and viral spread by looking for the presence of virus in the midgut and the rest of the body, respectively. All mosquitoes had similar levels of virus in the midgut, whether they had received DVGs or not, suggesting that DVGs had no significant impact on infection. However, mosquitoes that had received DVGs had significantly lower levels of virus in the rest of the body compared to control mosquitoes, suggesting that DVGs can reduce replication and spread of virus in mosquitoes.   

Because all experiments involved delivery of DVGs before or concurrently with wild type virus infection, it is unclear whether DVGs would have any therapeutic effect if they were applied after infection. Presently, the most feasible use for DVGs would be as a vector control strategy by engineering and releasing mosquitoes that are unable to transmit virus. However, considering that DVGs have immunostimulatory potential and their presence in humans correlates with milder disease and better outcome after influenza virus, respiratory syncytial virus, hepatitis C virus, and dengue virus infections, it would be interesting to see if they could be applied as direct therapeutics in humans. Using a combination of lab experiments and computational approaches, Vignuzzi and colleagues identified DVGs with optimal interference activity in a follow-up study. Based on these results, the French biotechnology company Meletios Therapeutics is currently developing a new class of antivirals against Zika virus and Chikungunya virus. This is exciting news, because there are currently no effective antiviral treatments for these two viral infections, and I look forward to following up on these new developments in a future post.  

TWiV 896: Memory B cells, the way we were

1 May 2022 2 Comments

TWiV explains a study of how climate change is predicted to increase cross-species viral transmission risk, and increased memory B cell potency and breadth after a SARS-CoV-2 mRNA vaccine boost.

Hosts: Vincent Racaniello, Dickson Despommier, and Amy Rosenfeld

Click arrow to play
Download TWiV 896 (65 MB .mp3, 108 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

TWiV 895: COVID-19 clinical update #112 with Dr. Daniel Griffin

30 April 2022 1 Comment

In COVID-19 clinical update #112, Dr. Griffin reviews seroprevalence of infection-induced antibodies, Moderna filing for vaccine authorization in young children, public health impact of vaccines in US, FDA approval of first treatment for young children, phase 2 data for Sabizabulin, and post infection inflammation.

Click arrow to play
Download TWiV 895 (33 MB .mp3, 54 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

TWiV 894: Dinner with the TMPRSS family

28 April 2022 Leave a Comment

TWiV explains what is known about cases of acute, severe hepatitis of unknown origin in children, and discovery of an inhibitor of TMPRSS2 protease that blocks SARS-CoV-2 infection.

Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker

Click arrow to play
Download TWiV 894 (60 MB .mp3, 100 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

Trial By Error: Now a Scottish Long Covid Study Fails to Mention the Risk of Post-Exertional Malaise

23 April 2022 5 Comments

By David Tuller, DrPH

*April is crowdfunding month at UC Berkeley. If you like my work, consider making a tax-deductible donation to Berkeley’s School of Public Health to support the Trial By Error project: https://crowdfund.berkeley.edu/project/31347

And here’s another major trial designed by investigators who think that an exercise program might be the optimal strategy for treating the complex grab-bag of conditions known as long Covid. As with other long Covid research, these investigators seem either unaware of or unconcerned about the core ME/CFS symptom known as post-exertional malaise (PEM)–also called post-exertional symptom exacerbation (PESE) or, in the ME-ICC case definition, post-exertional neuroimmune exhaustion (PENE).

[Read more…] about Trial By Error: Now a Scottish Long Covid Study Fails to Mention the Risk of Post-Exertional Malaise

TWiV 891: LLOV in the time of Ebola

21 April 2022

Elke, Adam, and Gabor join TWiV to discuss their work on Lloviu virus, a filovirus, including recovery of infectious virus from a DNA copy of the genome and from Schreiber’s bats in Hungary.

Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker

Guests: Elke Muhlberger, Adam Hume, and Gabor Kemenesi

Click arrow to play
Download TWiV 891 (65 MB .mp3, 108 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Show notes at microbe.tv/twiv

Next Page »

Primary Sidebar

by Vincent Racaniello

Earth’s virology Professor
Questions? virology@virology.ws

With David Tuller and
Gertrud U. Rey

Follow

Facebook, Twitter, YouTube, Instagram
Get updates by RSS or Email

Contents

Table of Contents
ME/CFS
Inside a BSL-4
The Wall of Polio
Microbe Art
Interviews With Virologists

Earth’s Virology Course

Virology Live
Columbia U
Virologia en Español
Virology 101
Influenza 101

Podcasts

This Week in Virology
This Week in Microbiology
This Week in Parasitism
This Week in Evolution
Immune
This Week in Neuroscience
All at MicrobeTV

Useful Resources

Lecturio Online Courses
HealthMap
Polio eradication
Promed-Mail
Small Things Considered
ViralZone
Virus Particle Explorer
The Living River
Parasites Without Borders

paulhasmeasles

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.